EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer

Iris S H Kloots, C Marleen Kets, Janneke Schuurs-Hoeijmakers, Leonie I Kroeze, Stephanie Pillay, Inge M van Oort, Haiko J Bloemendal, Winald R Gerritsen, Marjolijn J L Ligtenberg, Niven Mehra

European Journal of Cancer · 2026-11 · 248 · 117060

DOI: 10.1016/j.ejca.2026.117060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Iris S H Kloots und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Germ-Line Mutation, Genetic Testing, Biomarkers, Tumor. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Radboud Universitair Medisch Centrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGerm-Line MutationGenetic TestingBiomarkers, TumorHumansMaleProspective StudiesFanconi Anemia Complementation Group N ProteinAgedBRCA2 ProteinBRCA1 ProteinGenetic Predisposition to DiseaseMiddle AgedNeoplasm MetastasisAtaxia Telangiectasia Mutated ProteinsCheckpoint Kinase 2Referral and Consultation

Stichwörter der Autor:innen

Germline testingHomologous recombination repairMetastatic prostate cancerPrecision oncologyTumour first workflow

Substanzen

Fanconi Anemia Complementation Group N ProteinPALB2 protein, humanBRCA2 ProteinBRCA1 ProteinBRCA1 protein, humanBiomarkers, TumorBRCA2 protein, humanAtaxia Telangiectasia Mutated ProteinsCHEK2 protein, humanCheckpoint Kinase 2

Autor:innen und Institutionen

  • Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Department of Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Department of Urology, Radboud University Medical Centre, the Netherlands.
  • Department of Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Pathology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands. Electronic address: niven.mehra@radboudumc.nl.

Förderung

  • Radboud Universitair Medisch Centrum

Zitieren

APA

Kloots, I. S. H., Kets, C. M., Schuurs-Hoeijmakers, J., Kroeze, L. I., Pillay, S., van Oort, I. M., Bloemendal, H. J., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2026). Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer. European Journal of Cancer, 248, 117060. https://doi.org/10.1016/j.ejca.2026.117060

Vancouver

Kloots ISH, Kets CM, Schuurs-Hoeijmakers J, Kroeze LI, Pillay S, van Oort IM, et al. Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer. European Journal of Cancer. 2026;248:117060. doi:10.1016/j.ejca.2026.117060

BibTeX
@article{Kloots2026,
  author = {Kloots, Iris S H and Kets, C Marleen and Schuurs-Hoeijmakers, Janneke and Kroeze, Leonie I and Pillay, Stephanie and van Oort, Inge M and Bloemendal, Haiko J and Gerritsen, Winald R and Ligtenberg, Marjolijn J L and Mehra, Niven},
  title = {Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117060},
  doi = {10.1016/j.ejca.2026.117060}
}
Kostenlos starten →